In contrast to other cancer types where experimental SMARCA2 inhibition is synthetic lethal with SMARCA4 loss18–20, SMARCA2 silencing may cooperate with SMARCA4 loss in SMARCA4/2-deficient SCCOHT and NSCLC for cancer development10,21. Here, SMARCA4 is linked to non-small cell lung carcinoma.